Ingredient information should become a usable manufacturing control—not just a file attached to a purchase order. For dietary supplement teams, that means connecting a component specification, the incoming lot, the right test or examination, supplier documentation, and the decision to accept, quarantine, or investigate the material.
This is especially relevant as FDA continues to emphasize dietary-supplement CGMP expectations. A 2026 FDA warning letter again highlighted the need to establish specifications and determine whether they are met. The practical takeaway is straightforward: make each incoming component’s evidence trail clear before it moves into production.
What a component specification is designed to do
Under 21 CFR Part 111, manufacturers must establish specifications for each component used in dietary-supplement manufacturing. Those specifications cover identity and are also necessary to ensure the purity, strength, and composition of the finished dietary supplement; they also include limits on contamination that could adulterate, or lead to adulteration of, the finished batch.
A good specification is not a generic supplier datasheet. It is a controlled, product-relevant definition of what the manufacturing operation needs to receive and use. It should connect the component name and identifier with the characteristics, limits, sampling approach, methods, and acceptance criteria that matter for the intended formula.
Five practical elements to align before receipt
- Clear material identity. Use a controlled internal identifier and a precise description that matches purchasing, receiving, the bill of materials, and the label-development record.
- Relevant quality attributes. Identify attributes supporting the component’s intended role, including appropriate identity, purity, strength, composition, and contaminant limits.
- A documented method or examination. Select an approach that is scientifically valid and suitable for the particular material.
- Lot-level evidence. Link the supplier COA, receiving records, sampling records, results, and disposition decision to the incoming lot.
- A path for exceptions. Define what happens if a result, document, appearance, or traceability detail does not match the specification.
Identity testing: why the incoming-lot decision matters
FDA’s small-entity CGMP guide explains that a manufacturer must conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient before use, unless FDA grants a petitioned exemption. The guide also notes that a single test may be sufficient in some cases and that more than one may be needed in others.
That does not mean every material requires the same laboratory technique. The appropriate approach depends on the material and the specification. The key is to document the rationale: what was received, why the selected method or examination was appropriate, what result was obtained, who reviewed it, and how the lot was dispositioned.
When a supplier COA can help—and what it does not replace
A supplier certificate of analysis (COA) can be useful evidence when it is qualified and reliable. FDA’s CGMP guide states that manufacturers may determine whether other component specifications are met through appropriate tests or examinations or by relying on a supplier’s COA. When a manufacturer relies on a COA, Part 111 requires qualification of the supplier and periodic reconfirmation of the COA’s reliability through testing or examination.
In practice, this calls for a controlled supplier-qualification program. Teams should avoid treating a COA as a substitute for their own component specification or for required identity confirmation. Instead, consider it one part of the lot’s evidence package.
A simple receiving-to-release workflow
- Receive the lot under a controlled status and check its condition, labeling, quantity, and paperwork against the purchase order.
- Assign or confirm the internal lot identifier and link it to the approved component specification.
- Review the COA for completeness, expected methods, results, and lot traceability.
- Perform or arrange the required identity test or examination and any other defined verification activities.
- Document the results and quality review; release the material only after the required decision is complete.
- If a discrepancy appears, place the lot in the defined investigation or material-review process rather than informally overriding the record.
Build a data trail that follows the material
The strongest programs reduce friction between sourcing, quality, formulation, and production. A controlled data trail can connect the supplier and material specification to the master manufacturing record, batch production record, product specification, and finished-product review. That connection helps teams evaluate changes without losing sight of the formula or label requirements.
It is also useful when a supplier changes a source, specification, test method, or COA format. Rather than treating that as an administrative update, a change-control review can ask whether the material still meets the approved component specification and whether any downstream document needs revision.
Frequently asked questions
Is a supplier COA enough for dietary-ingredient identity?
Not by itself. FDA’s CGMP guide explains that manufacturers must verify the identity of dietary-ingredient components through at least one appropriate test or examination, unless FDA grants a petitioned exemption. A qualified supplier COA may support other component-specification determinations when applicable Part 111 requirements are met.
Does every ingredient need the same identity method?
No. The method or examination should be appropriate for the specific ingredient and the specification. The rationale, method, results, and quality decision should be documented.
How can a brand prepare for manufacturing discussions?
Bring a clear formula brief, intended dosage form, target market, ingredient documentation, and any known label constraints. Early review helps align sourcing, feasibility, testing, packaging, and production planning.
Planning a well-documented supplement project
Reaps Pharma supports brands developing capsules, tablets, gummies, powders, softgels, stick packs, and liquids with formulation planning and manufacturing coordination. Explore our dietary supplement OEM manufacturing services or contact our team to discuss a product brief.
This article is for general industry education and is not legal or regulatory advice. Dietary supplements are not FDA-approved before marketing; manufacturers and marketers remain responsible for meeting applicable requirements.